40 results
PRE 14A
ANEB
Anebulo Pharmaceuticals Inc
19 Oct 23
Preliminary proxy
5:18pm
and other benefits available in connection with a termination of employment and/or a change in control under the arrangements with our named executive … , the payment of severance benefits is subject to the named executive officer executing a general waiver and release of claims agreement within 30 days
8-K
EX-10.1
ANEB
Anebulo Pharmaceuticals Inc
6 Oct 23
Departure of Directors or Certain Officers
4:10pm
is employed by the Company on the date of the approval of the sale by the Board.
50,000 additional shares
(c) Benefits. The Executive is eligible … the Executive’s participation in, or benefits under, any employee benefit plans, programs or arrangements under Section 3(c), which amounts shall be payable
8-K
EX-10.1
6390s16v18f utkz
28 Sep 23
Departure of Directors or Certain Officers
6:17pm
8-K
EX-99.1
m0ozfo1
20 Sep 23
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2023
4:15pm
DEFR14A
poi ifha8
25 Oct 22
Revised proxy
5:27pm
8-K
EX-4.1
7g9gi4db4smlvzq81tq
29 Sep 22
Anebulo Pharmaceuticals Announces $6.6 million Private Placement Financing
4:05pm
8-K
ivascn m1w0ll
26 Sep 22
Regulation FD Disclosure
8:00am
8-K
EX-10.1
arhdo 8kflgmty4t0
24 May 22
Anebulo Pharmaceuticals Appoints Kenneth Cundy, Ph.D., as Chief Scientific Officer
4:05pm